文献速递生殖医学

PARP抑制剂奥拉帕利耗竭小鼠卵巢储备:对生育力保存的意义

The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
PubMed 文献 · Hum Reprod · 2020-01-01

该研究在小鼠中探究PARP抑制剂奥拉帕利单用或联合化疗对卵巢的影响。奥拉帕利单用使原始卵泡减少36%(P<0.05),但不加剧化疗介导的卵泡丢失;作者建议年轻女性在接受奥拉帕利治疗前考虑生育力保存。

要点

  • 奥拉帕利单用使小鼠原始卵泡显著减少36%(P<0.05),对其他卵泡类别无影响。
  • 奥拉帕利未加剧化疗介导的小鼠卵巢卵泡耗竭。
  • 作者建议年轻女性在接受奥拉帕利治疗前应考虑生育力保存。

核心结论

  • 奥拉帕利单用耗竭小鼠原始卵泡,但不加剧化疗介导的卵泡丢失;作者建议年轻女性在接受奥拉帕利治疗前应考虑生育力保存,并应优先开展人类研究。

研究设计与样本

  • 研究为小鼠实验,成年雌性野生型C57BL6/J小鼠(8周龄,生育力高峰),每组n=5。
  • 第0天腹腔注射单剂环磷酰胺(75 mg/kg体重)、多柔比星(10 mg/kg)、卡铂(80 mg/kg)、紫杉醇(7.5 mg/kg)或溶剂对照。
  • 第1至28天皮下给予奥拉帕利(50 mg/kg)或溶剂对照。

主要发现

  • 奥拉帕利组原始卵泡较对照组显著减少36%(P<0.05),其他卵泡类别、血清AMH、黄体数和动情周期无影响。
  • 原始卵泡残余在对照组卵巢中罕见检测到,在奥拉帕利单用组卵巢中显著升高(P<0.05)。
  • γH2AX灶指示的DNA损伤在对照组原始卵泡中完全检测不到,在奥拉帕利单用组约10%的存活原始卵泡卵母细胞中观察到。
  • 奥拉帕利未加剧化疗介导的野生型小鼠卵巢卵泡耗竭。

临床怎么用

  • 作者认为,数据提示年轻女性在接受奥拉帕利治疗前应考虑生育力保存选项,且该问题的人类研究应优先开展。
  • 作者指出,BRCA1和BRCA2突变携带者的卵泡耗竭程度可能更严重,这是当前研究的主题。

局限性

  • 研究在小鼠中进行, findings可能不能转化至女性,未来应使用人类卵巢组织和血清样本进一步研究。
  • 仅分析了一个长期时间点,未来应在更接近治疗的时间点评估奥拉帕利介导的卵泡损伤以支持机制发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the impact of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, alone or in combination with chemotherapy on the ovary in mice? SUMMARY ANSWER: Olaparib treatment, when administered alone, depletes primordial follicle oocytes, but olaparib does not exacerbate chemotherapy-mediated ovarian follicle loss in mice. WHAT IS KNOWN ALREADY: The ovary contains a finite number of oocytes stored within primordial follicles, which give rise to all mature ovulatory oocytes. Unfortunately, they are highly sensitive to exogenous DNA damaging insults, such as cytotoxic cancer treatments. Members of the PARP family of enzymes are central to the repair of single-strand DNA breaks. PARP inhibitors have shown promising clinical efficacy in reducing tumour burden, by blocking DNA repair capacity. Olaparib is a PARP1/2 inhibitor recently FDA-approved for treatment of BRCA1 and BRCA2 mutation carriers with metastatic breast cancer. It is currently being investigated as an adjunct to standard treatment at an earlier stage, potentially curable, BRCA1- and BRCA2-associated breast cancer which affects reproductive age women. Despite this, there is no preclinical or clinical information regarding the potential impacts of olaparib on the ovary or on female fertility. Unfortunately, it may be many years before clinical data on fertility outcomes for women treated with PARP inhibitors becomes available, highlighting the importance of rigorous preclinical research using animal models to establish the potential for new cancer therapies to affect the ovary in humans. We aimed to comprehensively determine the impact of olaparib alone, or following chemotherapy, on the ovary in mice. STUDY DESIGN, SIZE, DURATION: On Day 0, mice (n = 5/treatment group) were administered a single intraperitoneal dose of cyclophosphamide (75 mg/kg/body weight), doxorubicin (10 mg/kg), carboplatin (80 mg/kg), paclitaxel (7.5 mg/kg) or vehicle control. From Days 1 to 28, mice were administered subcutaneous olaparib (50 mg/kg) or vehicle control. This regimen is proven to reduce tumour burden in preclinical mouse studies and is also physiologically relevant for women. PARTICIPANTS/MATERIALS, SETTING, METHODS: Adult female wild-type C57BL6/J mice at peak fertility (8 weeks) were administered a single intraperitoneal dose of chemotherapy, or vehicle, then either subcutaneous olaparib or vehicle for 28 days. Vaginal smears were performed on each animal for 14 consecutive days from Days 15 to 28 to monitor oestrous cycling. At 24 h after final treatment, ovaries were harvested for follicle enumeration and immunohistochemical analysis of primordial follicle remnants (FOXL2 expressing granulosa cells), DNA damage (γH2AX) and analysis of apoptosis by TUNEL assay. Serum was collected to measure circulating anti-Müllerian hormone (AMH) concentrations by ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Olaparib significantly depleted primordial follicles by 36% compared to the control (P < 0.05) but had no impact on other follicle classes, serum AMH, corpora lutea number (indicative of ovulation) or oestrous cycling. Primordial follicle remnants were rarely detected in control ovaries but were significantly elevated in ovaries from mice treated with olaparib alone (P < 0.05). Similarly, DNA damage denoted by γH2AX foci was completely undetectable in primordial follicles of control animals but was observed in ∼10% of surviving primordial follicle oocytes in mice treated with olaparib alone. These observations suggest that functional PARPs are essential for primordial follicle oocyte maintenance and survival. Olaparib did not exacerbate chemotherapy-mediated follicle depletion in the wild-type mouse ovary. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: This study was performed in mice, so the findings may not translate to women and further studies utilizing human ovarian tissue and sera samples should be performed in the future. Only one long-term time point was analysed, therefore olaparib-mediated follicle damage should be assessed at more immediate time points in the future to support our mechanistic findings. WIDER IMPLICATIONS OF THE FINDINGS: Olaparib dramatically depleted primordial follicles and this could be attributed to loss of intrinsic PARP-mediated DNA repair mechanisms. Importantly, diminished ovarian reserve can result in premature ovarian insufficiency and infertility. Notably, the extent of follicle depletion might be enhanced in BRCA1 and BRCA2 mutation carriers, and this is the subject of current investigations. Together, our data suggest that fertility preservation options should be considered for young women prior to olaparib treatment, and that human studies of this issue should be prioritized. STUDY FUNDING/COMPETING INTEREST(S): This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. This work was supported by funding from the National Health and Medical Research Council (NHMRC); (K.J.H. #1050130) (A.L.W. #1120300). K.A.P. is a National Breast Cancer Foundation Fellow (Australia-PRAC-17-004). K.A.P. is the Breast Cancer Trials (Australia) Study Chair for the OlympiA clinical trial sponsored by AstraZeneca, the manufacturer of olaparib. All other authors declare no competing financial or other interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Winship AL, Griffiths M, Lliberos Requesens C, et al. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020. PMID: 32604417. doi:10.1093/humrep/deaa128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。